Targeted supplements: Data indicates that calorie intake reduces by 16-39% while taking a GLP1 medication (Spreckley 2026)
Pocock et al
Semaglutide users who took a weekly dose of 2.4 mg for 68 weeks, or roughly 15 months, dropped an average of 35 pounds, or 15% of their body weight, compared to 2.4% for the placebo group
Canagliflozin significantly inhibits inflammatory factor expression, including cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase, exerting cardioprotective effects by regulating inflammation and ferroptosis through the AMP-activated protein kinase (AMPK) pathway (83)
Every GLP-1 medication available through Amazon's program is an FDA-approved branded product Wegovy, Zepbound, Foundayo, or oral Wegovy manufactured by Novo Nordisk or Eli Lilly
Studies demonstrate 10-15% body weight reductions, positioning it as a powerful tool for obesity mechanism investigations